Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab or Retlirafusp Alfa + Recaticimab + Chemotherapy in Resectable NSCLC
NCT07567326Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
01
Overview
A Phase 2 trial of adebrelimab, retlirafusp alfa, recaticimab in non-small cell lung cancer (NSCLC), sponsored by Peking University Cancer Hospital & Institute. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
adebrelimabretlirafusp alfarecaticimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07567326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07567326.